New shot for obesity and diabetes passes first safety test
NCT ID NCT05925920
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tested a single injection of a new drug called ENT-03S in 49 people who were either obese but otherwise healthy, or had both obesity and type 2 diabetes. The main goal was to check safety and how the drug moves through the body. Participants were randomly assigned to receive either the drug or a placebo, and were monitored for two weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ENT-03S
What this could lead to
If successful, this could point toward a new injectable treatment for obesity and type 2 diabetes.
What could go wrong
This is a very early Phase 1 trial with only 49 people, focused on safety and dosing. It is too small to prove effectiveness, and many early-stage drugs do not advance.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ProSciento
San Diego, California, 91911, United States